ACADIA to Host Conference Call and Webcast on Wednesday, May 10, 2006, at5:00 p.m. Eastern Time
SAN DIEGO, May 3 /PRNewswire-FirstCall/ —ACADIA Pharmaceuticals Inc.(Nasdaq: ACAD), a biopharmaceutical company utilizing innovative technology tofuel drug discovery and clinical development of novel treatments for centralnervous system disorders, today announced that it will report its unauditedfinancial results for the first quarter ended March 31, 2006 on Wednesday,May 10, 2006, after the U.S. financial markets close.
Uli Hacksell, Ph.D., Chief Executive Officer, and Thomas H. Aasen, VicePresident and Chief Financial Officer, will host a conference call and webcaston Wednesday, May 10, 2006 at 5:00 p.m. Eastern Time to discuss ACADIA'sfinancial results and provide an update on the company's development programs.
The conference call may be accessed by dialing 866-713-8395 forparticipants in the U.S. or Canada and 617-597-5309 for international callers(reference passcode 76699715). A telephone replay of the conference call maybe accessed through May 24, 2006 by dialing 888-286-8010 for callers in theU.S. or Canada and 617-801-6888 for international callers (reference passcode24798056). The conference call also will be webcast live on ACADIA's website,www.acadia-pharm.com, under the investors section and will be archived thereuntil May 24, 2006.
About ACADIA Pharmaceuticals
ACADIA is a biopharmaceutical company utilizing innovative technology tofuel drug discovery and clinical development of novel treatments for centralnervous system disorders. ACADIA currently has five Phase II-stage clinicalprograms as well as a portfolio of preclinical and discovery assets directedat large unmet medical needs, including schizophrenia, Parkinson's disease,sleep maintenance insomnia, and neuropathic pain. All of the drug candidatesin ACADIA's product pipeline emanate from discoveries made using itsproprietary drug discovery platform. ACADIA's corporate headquarters islocated in San Diego, California and it maintains research and developmentoperations in both San Diego and Malmo, Sweden.
Contacts:
ACADIA Pharmaceuticals Inc.
Lisa Barthelemy, Director, Investor Relations
Thomas H. Aasen, Vice President and Chief Financial Officer
(858) 558-2871